BCLI — BRAINSTORM CELL THERAPEUTICS INC.
—
OTC ·
Health Care ·
Biotechnology ·
CIK 1137883 ·
Last close
$0.97
Market Cap
$10.70M
52W High
$1.69
52W Low
$0.46
ADV30
32,030
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -3,613,000 | -3,855,000 | 788,000 | 22,000 | 12,385,000 |
| Mar 2026 | 0 | — | -2,046,000 | -2,127,000 | 755,000 | 15,000 | 11,764,000 |
| Dec 2025 | 0 | — | -2,244,000 | -2,434,000 | 1,022,000 | 29,000 | 11,007,000 |
| Sep 2025 | 0 | — | -2,047,000 | -2,106,000 | 1,380,000 | 5,000 | 9,073,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-6,664,000
Investing CF
$12,000
Financing CF
$5,044,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.17
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-239,070,000
Inventory
—
Receivables
$122,000
ST Investments
—
EBIT TTM
$-8,910,000
Pretax Income TTM
$-9,570,000
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -9,953,000 | -10,307,000 | 1,022,000 | 11,007,000 | -9,985,000 | -6,975,000 |
| Dec 2024 | 0 | -11,693,000 | -11,623,000 | 1,832,000 | 9,596,000 | -7,764,000 | -9,093,000 |
| Dec 2023 | 0 | -21,439,000 | -17,192,000 | 4,208,000 | 9,066,000 | -4,858,000 | -20,458,000 |
| Dec 2022 | 0 | -24,822,000 | -24,277,000 | 8,451,000 | 11,466,000 | -3,015,000 | -19,320,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.02
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ZEOX | Zeo ScientifiX, Inc. | $10.66M | $1.36 | — |
| SNTI | Senti Biosciences Holdings, Inc. | $10.25M | $0.33 | — |
| INAB | IN8BIO, INC. | $11.83M | $1.20 | — |
| INTS | INTENSITY THERAPEUTICS, INC. | $12.41M | $3.80 | — |
| PLUR | Pluri Inc. | $12.47M | $1.01 | — |
News headlines (Yahoo Finance, 1h cache)
BrainStorm Executive Leadership to Participate in DUPHAT 2026; Executive Chairman Peter J. Pitts Invited to Deliver Two Keynote Addresses and Moderate Panel Sessions
2026-08-24 12:15 · Yahoo
BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-14 20:00 · Yahoo
BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine
2026-06-02 13:00 · Yahoo
BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors
2026-05-28 11:45 · Yahoo
BrainStorm Cell Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-15 20:05 · Yahoo
BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update
2026-03-31 20:01 · Yahoo
BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman
2026-07-28 12:00 · Yahoo
BrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market
2026-05-19 12:00 · Yahoo
Brainstorm Cell Therapeutics Secures Second $1 Million Strategic Placement; Total $2 Million Raised In February
2026-02-26 11:22 · Yahoo
Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing at Premium to Market
2026-02-20 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.